Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: September 10, 2003
Last updated: September 2, 2012
Last verified: September 2009

RATIONALE: Drugs used in chemotherapy such as cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy with radiation therapy before surgery may shrink the tumor so it can be removed during surgery.

PURPOSE: This phase II trial is studying how well giving radiation therapy together with cisplatin followed by surgery works in treating patients with locally advanced cancer of the vulva.

Condition Intervention Phase
Vulvar Cancer
Drug: cisplatin
Procedure: adjuvant therapy
Procedure: conventional surgery
Radiation: radiation therapy
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Complete clinical and pathologic tumor response at completion of treatment [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Toxicity weekly during treatment then every 3 months after treatment [ Designated as safety issue: Yes ]

Estimated Enrollment: 58
Study Start Date: January 2005
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the efficacy of radiotherapy and cisplatin, in terms of achieving a complete clinical and pathological response, in patients with locally advanced squamous cell carcinoma of the vulva that is not amenable to standard radical vulvectomy.
  • Determine the toxicity of this regimen followed by surgery in these patients.

OUTLINE: This is a multicenter study.

Patients undergo radiotherapy daily on days 1-5 and receive concurrent cisplatin IV over 30 minutes on day 1. Treatment repeats weekly for approximately 6.5 weeks (a total of 32 fractions of radiotherapy) in the absence of unacceptable toxicity.

Six to eight weeks after the completion of chemoradiotherapy, patients with a complete clinical response may undergo incisional biopsy of the primary tumor and bilateral inguinal/femoral nodes (if the groin nodes were initially unresectable). Patients with microscopic or gross resectable residual disease may then undergo radical resection of the residual tumor. Patients with unresectable disease after the completion of chemoradiotherapy receive additional radiotherapy with 1-2 courses of concurrent cisplatin.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 25-58 patients will be accrued for this study within 1.8-2.3 years.


Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Diagnosis of locally advanced squamous cell carcinoma of the vulva

    • T3 or T4 (N0-3, M0)
  • Not amenable to surgical resection by standard radical vulvectomy
  • Previously untreated disease
  • No recurrent disease
  • No vulvar melanoma or sarcoma



  • Any age

Performance status

  • GOG 0-3

Life expectancy

  • Not specified


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 1.5 times normal
  • Alkaline phosphatase no greater than 3 times normal
  • SGOT no greater than 3 times normal


  • Creatinine no greater than 2.0 mg/dL


  • No gastrointestinal bleeding
  • No severe gastrointestinal symptoms


  • Capable of tolerating a radical course of chemoradiotherapy
  • No septicemia
  • No severe infection
  • No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
  • No circumstance that would preclude study completion or follow-up


Biologic therapy

  • Not specified


  • No prior cytotoxic chemotherapy

Endocrine therapy

  • Not specified


  • No prior pelvic radiotherapy
  • No concurrent boost brachytherapy


  • Not specified


  • No prior anticancer therapy that would contraindicate study therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00068406

  Show 113 Study Locations
Sponsors and Collaborators
Gynecologic Oncology Group
National Cancer Institute (NCI)
Study Chair: David H. Moore, MD Gynecologic Oncology of Indiana
Investigator: Wui-jin Koh, MD Fred Hutchinson Cancer Research Center
  More Information

Additional Information:
Responsible Party: Philip J. DiSaia, Gynecologic Oncology Group Identifier: NCT00068406     History of Changes
Other Study ID Numbers: CDR0000322259, GOG-0205
Study First Received: September 10, 2003
Last Updated: September 2, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
squamous cell carcinoma of the vulva
stage III vulvar cancer
stage IVB vulvar cancer

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Vulvar Neoplasms
Genital Diseases, Female
Genital Neoplasms, Female
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Urogenital Neoplasms
Vulvar Diseases processed this record on November 27, 2015